For personal use only

15 March 2022

Company Announcements Office

Australian Securities Exchange

Issue of Shares

Vectus Biosystems Limited (ASX:VBS) (Vectus or the Company) advises that it has issued a total of

351,163 fully paid ordinary shares as follows:

  • A total of 330,000 fully paid ordinary shares to a note holder following the conversion of 330,000 convertible notes, at a conversion price of $0.50 per note.
  • In relation to the accumulated interest on these notes, at an interest rate of 6% per annum and as provided for in the Convertible Note Deed, the interest was paid as a total of 21,163 fully paid ordinary shares calculated at $1.22 per share.

Attached is an Appendix 2A for the above share issue.

Cleansing Notice Under Section 708A(5)(e)

Vectus advises that on 14 March 2022 the Company issued a total of 351,163 fully paid ordinary shares, as set out above. Vectus advises that:

  1. this notice is being given within five business days after the day of the issue under section 708A(5)(e) of the Corporations Act 2001 (Cth);
  2. the Company issued the securities without disclosure to investors under Part 6D.2 of the Corporations Act 2001;
  3. as at the date of this notice, VBS has complied with:
    1. the provisions of Chapter 2M of the Corporations Act 2001 as they apply to the Company; and
    2. section 674 of the Corporations Act 2001; and
  5. except as may be set out in this notice, there is no other information that is excluded information as at the date of this notice that is required to be set out in this notice under section 708A(6)(e) of the Corporations Act 2001.

Vectus Biosystems Limited

Robert J Waring

Company Secretary

This announcement was authorised by the Company Secretary.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9381 1000 Facsimile: +61 2 9662 1720

Website: www.vectusbiosystems.com.au

For personal use only

This appendix is available as an online form

Only use this form if the online version is not available

+Rule 2.8, 3.10.3A to 3.10.3D

Appendix 2A

Application for quotation of +securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

If you are an entity incorporated outside Australia and you are seeking quotation of a new class of +securities other than CDIs, you will need to obtain and provide an International Securities Identification Number (ISIN) for that class. Further information on the requirement for the notification of an ISIN is available from the Create Online Forms page. ASX is unable to create the new ISIN for non-Australian issuers.

*Denotes minimum information required for first lodgement of this form, with exceptions provided in specific notes for certain questions. The balance of the information, where applicable, must be provided as soon as reasonably practicable by the entity.

Part 1 - Entity and announcement details

Question

Question

Answer

no

1.1

*Name of entity

Vectus Biosystems Limited

We (the entity here named) apply for

+quotation of the following +securities and

agree to the matters set out in

Appendix 2A of the ASX Listing Rules.1

1.2

*Registration type and number

ABN 54 117 526 137

Please supply your ABN, ARSN, ARBN, ACN or

another registration type and number (if you supply

another registration type, please specify both the type

of registration and the registration number).

1.3

*ASX issuer code

1.4

*This announcement is

☒ A new announcement

Tick whichever is applicable.

☐ An update/amendment to a

previous announcement

☐ A cancellation of a previous announcement

1.4a

*Reason for update

Not Applicable

Answer this question if your response to Q 1.4 is an

update/amendment to previous announcement.

1.4b

*Date of previous announcement to this update

Not Applicable

Answer this question if your response to Q 1.4 is an

update/amendment to previous announcement.

1.4c

*Reason for cancellation

Not applicable

Answer this question if your response to Q 1.4 is "A

cancellation of a previous announcement"

1.4d

*Date of previous announcement to

Not applicable

this cancellation

Answer this question if your response to Q 1.4 is "A

cancellation of a previous announcement"

1.5

*Date of this announcement

15 March 2022

1 Appendix 2A of the Listing Rules includes a warranty that an offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or 1012C(6) of the Corporations Act. If you are in any doubt as to the application of, or the entity's capacity to give, this warranty, please see ASIC Regulatory Guide 173 Disclosure for on-saleof securities and other financial products and consult your legal adviser.

+ See chapter 19 for defined terms

5 June 2021

Page 1

For personal use only

This appendix is available as an online form

Appendix 2A

Application for quotation of +securities

Part 2 - Type of issue

Question

Question

Answer

No.

2.1

*The +securities to be quoted are:

☐ +Securities issued as part of a

Select whichever item is applicable.

transaction or transactions previously

If you wish to apply for quotation of different types of

announced to the market in an

issues of securities, please complete a separate

Appendix 3B

Appendix 2A for each type of issue.

☐ +Securities issued under a +dividend or

distribution plan

☒ +Securities issued, transferred or re-

classified as a result of options being

exercised or other +convertible

securities being converted

☐ Unquoted partly paid +securities that

have been fully paid up and are now to

become quoted fully paid +securities

Note: there is no need to apply for quotation of

the fully paid securities if the partly paid securities

were already quoted

☐ +Restricted securities where the escrow

period has expired or is about to expire

☐ +Securities previously issued under an

+employee incentive scheme where the

restrictions on transfer have ceased or

are about to cease

☐ +Securities issued under an +employee

incentive scheme that are not subject to

a restriction on transfer or that are to be

quoted notwithstanding there is a

restriction on transfer

☒ Other [please specify]

If you have selected 'other' please explain the

circumstances of the issue here:

A total of 21,163 fully paid ordinary shares

to a convertible note holder representing

accumulated interest on converted notes at

an interest rate of 6% per annum, and

converted at $1.22 per share.

2.1a

*Have the +securities to be quoted been

Yes

issued yet?

2.1a.1

*What was their date of issue?

14 March 2022

Answer this question if your response to Q2.1a is "Yes".

2.1a.2

*What is their proposed date of issue?

Not Applicable

Answer this question if your response to Q2.1a is "No".

2.2a.1

*Date of Appendix 3B notifying the market

Not Applicable

of the proposed issue of +securities for

which quotation is now being sought

Answer this question if your response to Q2.1 is

"Securities issued as part of a transaction or transactions

previously announced to the market in an Appendix 3B"

+ See chapter 19 for defined terms

5 June 2021

Page 2

This appendix is available as an online form

Appendix 2A

Application for quotation of +securities

2.2a.2

*Are there any further issues of +securities

Not Applicable

yet to take place to complete the

transaction(s) referred to in the Appendix 3B?

only

Answer this question if your response to Q2.1 is

"Securities issued as part of a transaction or transactions

previously announced to the market in an Appendix 3B".

2.2a.2.1

*Please provide details of the further issues of

Not Applicable

+securities yet to take place to complete the

transaction(s) referred to in the Appendix 3B

Answer this question if your response to Q2.1 is

"Securities issued as part of a transaction or

transactions previously announced to the market in an

Appendix 3B" and your response to Q2.2a.2 is "Yes".

Please provide details of the proposed dates and

use

number of securities for the further issues. This may

be the case, for example, if the Appendix 3B related to

an accelerated pro rata offer with an institutional

component being quoted on one date and a retail

component being quoted on a later date.

2.2b.1

Date of Appendix 3A.1 lodged with ASX in

Not Applicable

relation to the underlying +dividend or distribution

Answer this question if your response to Q2.1 is

"Securities issued under a dividend or distribution plan".

personal

2.2c.1

Please state the number and type of

330,000 convertible notes converted

options that were exercised or other

(ASX:VBSAE), held by a note holder, at a

+convertible securities that were converted

conversion price of $0.50 per convertible note.

(including their ASX security code)

Answer this question if your response to Q2.1 is

"Securities issued, transferred or re-classified as a

result of options being exercised or other convertible

securities being converted".

2.2c.2

And the date the options were exercised or

11 March 2022

other +convertible securities were converted

Answer this question if your response to Q2.1 is

"Securities issued, transferred or re-classified as a

result of options being exercised or other convertible

securities being converted".

Note: If this occurred over a range of dates, enter the

first date and last date of the period in which the options

were exercised or convertible securities were converted.

2.2c.3

Is this all of the options or other

No

For

+convertible securities on issue of that type

The remaining 10,520,000 Convertible Notes

(i.e. have all of those options now been

exercised or have all of those convertible

have a maturity date of 27 September 2022.

securities now been converted)?

Answer this question if your response to Q2.1 is

Note: If you have answered "No", consider whether you

"Securities issued, transferred or re-classified as a

need to lodge an Appendix 3H with ASX notifying ASX

result of options being exercised or other convertible

of the cessation of some or all of the remaining options

securities being converted".

or other convertible securities under Listing Rule 3.10.E.

This may the case, for example, if options have lapsed

because they have passed their expiry date without

being exercised, or convertible debt securities have

been repaid or redeemed without being converted.

2.2c.4

The right of the holder of the options or

☒ An issue of new +securities

other +convertible securities to receive the

☐ A transfer of existing +securities

+underlying securities is being satisfied by:

☐ A reclassification of the +convertible

Answer this question if your response to Q2.1 is

securities as securities in the same

"Securities issued, transferred or re-classified as a

result of options being exercised or other convertible

class as the +underlying securities

securities being converted".

+ See chapter 19 for defined terms

5 June 2021

Page 3

This appendix is available as an online form

Appendix 2A

Application for quotation of +securities

2.2c.5

The underlying securities being received by

☒ Already quoted by ASX

the holder are:

☐ Intended to be, but are not yet, quoted

Answer this question if your response to Q2.1 is

by ASX

only

"Securities issued, transferred or re-classified as a

result of options being exercised or other convertible

☐ Are not, and are not intended to be,

securities being converted".

quoted by ASX

2.2c.6

Were the options being exercised or other

No

+convertible securities being converted issued

under an +employee incentive scheme?

Answer this question if your response to Q2.1 is

"Securities issued, transferred or re-classified as a

result of options being exercised or other convertible

securities being converted".

use

2.2c.7

*Are any of the options being exercised or

Yes

other +convertible securities being

converted held by +key management

personnel (KMP) or an +associate?

Answer this question if your response to Q2.1 is

"Securities issued, transferred or re-classified as a result

of options being exercised or other convertible securities

being converted" and your response to Q2.2c.6 is "Yes".

2.2c.7.a

*Provide details of the KMP or +associates who are exercising options or converting

personal

convertible securities.

Answer this question if your response to Q2.1 is "Securities issued, transferred or re-classified as a result of

options being exercised or other convertible securities being converted", your response to Q2.2c.6 is "Yes" and

your response to Q2.2c.7 is "Yes". Repeat the detail in the table below for each KMP involved. If the options or

other convertible securities are held by the KMP, repeat the name of the KMP or insert "Same" in "Name of

registered holder". If the options or other convertible securities are held by an associate of a KMP, insert the

name of the associate in "Name of registered holder".

Name of KMP

Name of registered holder

Number of options

[200 characters]

[200 characters]

being exercised or other

+convertible securities

being converted

[16 characters]

Not applicable

Not applicable

Not applicable

2.2d.1

Please state the number and type of

Not applicable

unquoted partly paid +securities (including

their ASX security code) that have been

fully paid up and that are now to become

For

quoted on ASX

Answer this question if your response to Q2.1 is "Partly

paid securities that have been fully paid up and are

now to become quoted fully paid securities".

2.2d.2

And the date the +securities were fully paid up

Not applicable

Answer this question if your response to Q2.1 is "Partly

paid securities that have been fully paid up and are

now to become quoted fully paid securities".

Note: If this occurred over a range of dates, enter the

date the last of the securities was fully paid up.

2.2d.3

Is this all of the partly paid +securities on

Not applicable

issue of that type (i.e. have all of those partly

paid securities now been fully paid up)?

Answer this question if your response to Q2.1 is

"Unquoted partly paid securities that have been fully paid

up and are now to become quoted fully paid securities".

+ See chapter 19 for defined terms

5 June 2021

Page 4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Vectus Biosystems Ltd. published this content on 14 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 March 2022 23:29:06 UTC.